Keywords
Abstract
A prospective clinical study was conducted involving 70 patients with angle-closure glaucoma treated at the Andijan Regional Ophthalmology Hospital. Baseline intraocular pressure, visual acuity, optic nerve status, and visual field parameters were assessed before treatment initiation. Patients received miotics, β-adrenergic blockers, carbonic anhydrase inhibitors, or their combinations. Follow-up examinations evaluated changes in intraocular pressure, visual function, and drug tolerability.
The study demonstrated a significant reduction in intraocular pressure in all treatment groups, with the most pronounced and sustained effect observed in patients receiving combination therapy. Individualized selection of antihypertensive regimens improved treatment effectiveness and safety in patients with angle-closure glaucoma.
References
Sharif N. A. Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients // Pharmaceuticals. 2023. Vol. 16, No. 6. Article 791. DOI: 10.3390/ph16060791.
Patton G.N., Lee H.J. Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches // Pharmaceutics. 2024. Vol. 16, No. 2. Article 274. DOI: 10.3390/pharmaceutics16020274.
Hallaj S., Shalaby W.S., Sinha S. et al. Systemic Carbonic Anhydrase Inhibitors in Common Ophthalmic Diseases: A Scoping Review from A Clinical Standpoint // Current Ophthalmology Reports. 2025. Vol. 13, Article 9. DOI: 10.1007/s40135-025-00332-x.